Vicarious Surgical (RBOT) Competitors $6.55 +0.65 (+11.00%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RBOT vs. BSGM, LNSR, RCEL, AVR, LAKE, MBOT, PDEX, PROF, LUCD, and HYPRShould you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Biosig Technologies (BSGM), LENSAR (LNSR), Avita Medical (RCEL), Anteris Technologies Global (AVR), Lakeland Industries (LAKE), Microbot Medical (MBOT), Pro-Dex (PDEX), Profound Medical (PROF), Lucid Diagnostics (LUCD), and Hyperfine (HYPR). These companies are all part of the "medical equipment" industry. Vicarious Surgical vs. Its Competitors Biosig Technologies LENSAR Avita Medical Anteris Technologies Global Lakeland Industries Microbot Medical Pro-Dex Profound Medical Lucid Diagnostics Hyperfine Vicarious Surgical (NYSE:RBOT) and Biosig Technologies (NASDAQ:BSGM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation. Does the media favor RBOT or BSGM? In the previous week, Vicarious Surgical had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 5 mentions for Vicarious Surgical and 4 mentions for Biosig Technologies. Vicarious Surgical's average media sentiment score of 0.13 beat Biosig Technologies' score of -0.23 indicating that Vicarious Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biosig Technologies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in RBOT or BSGM? 47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 12.0% of Vicarious Surgical shares are held by company insiders. Comparatively, 24.8% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, RBOT or BSGM? Biosig Technologies has higher revenue and earnings than Vicarious Surgical. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVicarious SurgicalN/AN/A-$63.22M-$10.09-0.65Biosig Technologies$40K3,950.28-$10.33MN/AN/A Is RBOT or BSGM more profitable? Vicarious Surgical's return on equity of -148.14% beat Biosig Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Vicarious SurgicalN/A -148.14% -98.07% Biosig Technologies N/A -10,930.60%-90.03% Which has more risk & volatility, RBOT or BSGM? Vicarious Surgical has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Do analysts recommend RBOT or BSGM? Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 6.89%. Biosig Technologies has a consensus target price of $10.00, indicating a potential upside of 98.85%. Given Biosig Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Biosig Technologies is more favorable than Vicarious Surgical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Biosig Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryBiosig Technologies beats Vicarious Surgical on 8 of the 12 factors compared between the two stocks. Get Vicarious Surgical News Delivered to You Automatically Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RBOT vs. The Competition Export to ExcelMetricVicarious SurgicalMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$38.91M$6.86B$5.76B$20.89BDividend YieldN/A1.29%4.53%3.60%P/E Ratio-0.6526.5630.4328.30Price / SalesN/A66.17392.2152.84Price / CashN/A21.6837.0323.77Price / Book1.686.759.015.18Net Income-$63.22M$176.42M$3.26B$992.10M7 Day Performance-12.28%-2.53%1.00%-0.36%1 Month Performance-36.97%-2.23%4.19%1.14%1 Year Performance-5.77%7.85%28.39%10.37% Vicarious Surgical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RBOTVicarious Surgical0.8176 of 5 stars$6.55+11.0%$7.00+6.9%-6.0%$38.91MN/A-0.65210BSGMBiosig Technologies1.9499 of 5 stars$5.48+10.3%$10.00+82.5%+995.1%$156.15M$40K0.0050Earnings ReportGap DownHigh Trading VolumeLNSRLENSAR1.0414 of 5 stars$12.75+0.8%$15.00+17.6%+209.1%$150.98M$53.49M-3.03110Negative NewsRCELAvita Medical1.445 of 5 stars$5.55-1.4%$12.40+123.4%-47.1%$149.87M$64.25M-2.82130News CoverageAVRAnteris Technologies GlobalN/A$3.80-5.9%$16.50+334.2%N/A$145.69M$2.70M0.00138Positive NewsLAKELakeland Industries4.1483 of 5 stars$15.06+0.6%$26.00+72.6%-38.0%$142.43M$167.21M-5.002,100MBOTMicrobot Medical1.8662 of 5 stars$3.08-0.3%$9.00+192.2%+221.4%$140.74MN/A-5.3120News CoverageOptions VolumePDEXPro-Dex1.6783 of 5 stars$44.10+3.2%$56.00+27.0%+124.3%$139.34M$64.12M15.75140PROFProfound Medical1.7598 of 5 stars$4.75+11.8%$11.00+131.6%-51.1%$127.73M$10.68M-3.25150Earnings ReportGap UpHigh Trading VolumeLUCDLucid Diagnostics1.9574 of 5 stars$1.02flat$3.55+248.0%+22.3%$110.65M$4.35M-0.8670Gap DownHYPRHyperfine1.5453 of 5 stars$1.29-7.2%$1.28-0.5%+22.5%$108.19M$12.89M-2.48190Analyst RevisionGap Up Related Companies and Tools Related Companies BSGM Alternatives LNSR Alternatives RCEL Alternatives AVR Alternatives LAKE Alternatives MBOT Alternatives PDEX Alternatives PROF Alternatives LUCD Alternatives HYPR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RBOT) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vicarious Surgical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vicarious Surgical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access